BiotechTube

adalimumab + adalimumab + placebo

Phase 2/3Completed
2 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Feb 1, 2007 → —

NCT ID
NCT00445939

About adalimumab + adalimumab + placebo

adalimumab + adalimumab + placebo is a phase 2/3 stage product being developed by Eisai for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00445939. Target conditions include Crohn's Disease.

What happened to similar drugs?

9 of 20 similar drugs in Crohn's Disease were approved

Approved (9) Terminated (4) Active (11)
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved
✅Cimzia + MesalamineUCBApproved
✅Certolizumab PegolUCBApproved
✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00445939Phase 2/3Completed

Competing Products

20 competing products in Crohn's Disease

See all competitors
ProductCompanyStageHype Score
CT-P13 + RemicadeCelltrionPhase 3
40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
CP-461Astellas PharmaPhase 2
35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
MirikizumabEli LillyPhase 3
44
Matching Placebo for Upadacitinib + UpadacitinibAbbViePhase 3
40
Adalimumab + PlaceboAbbViePhase 3
40
Upadacitinib + Placebo for UpadacitinibAbbViePhase 3
40
Placebo + ABT-494AbbViePhase 2
35
ABT-494AbbViePhase 2
35
Risankizumab + ComparatorAbbViePre-clinical
33
placebo for risankizumab + risankizumab IV + risankizumab SCAbbViePhase 3
40